EAM Investors’s Voyager Therapeutics VYGR Stock Holding History

EAM Investors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-187,502	Closed	-$2.15M	–	390
2023 Q2	$2.15M	Buy	187,502 +63,684	+51%	+$659K	0.4%	95
2023 Q1	$955K	Buy	+123,818	New	+$985K	0.19%	233
2022 Q2	–	Sell	-339,497	Closed	-$2.59M	–	362
2022 Q1	$2.59M	Buy	+339,497	New	+$1.51M	0.48%	66
2019 Q3	–	Sell	-38,653	Closed	-$1.05M	–	301
2019 Q2	$1.05M	Buy	+38,653	New	+$885K	0.26%	184
2018 Q2	–	Sell	-31,905	Closed	-$599K	–	356
2018 Q1	$599K	Buy	+31,905	New	+$690K	0.1%	258

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM Investors's VYGR Position: Q3 2023 in Review

EAM Investors sold out of Voyager Therapeutics (VYGR) in Q3 2023, closing a stake of 187,502 shares — an estimated $2.15M sold.

EAM Investors first reported a position in VYGR in Q1 2018 and held it in 5 quarters. The position peaked at $2.59M in Q1 2022. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2023.

EAM Investors reported no remaining Voyager Therapeutics position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 187,502 Voyager Therapeutics shares in Q3 2023, an estimated $2.15M.
EAM Investors first reported a position in Voyager Therapeutics in Q1 2018 and held it in 5 quarters.
EAM Investors's Voyager Therapeutics position peaked at $2.59M in Q1 2022.
110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.